Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Clover Biopharmaceuticals Ltd. ( (HK:2197) ) has issued an announcement.
Clover Biopharmaceuticals Ltd. announced the grant of 5,964,000 options and 9,016,500 restricted stock units (RSUs) to eligible participants under its Post-IPO Share Option Plan and RSU Scheme. The options and RSUs are part of the company’s strategy to incentivize and retain talent by aligning employee and stakeholder interests with company performance. The options have a 10-year validity, with vesting conditions tied to group and individual performance targets, reflecting the company’s commitment to achieving long-term growth and operational success.
More about Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals Ltd. is a company incorporated in the Cayman Islands, operating in the biopharmaceutical industry. The company is primarily focused on developing and commercializing vaccines and biologic therapeutic products.
YTD Price Performance: -7.08%
Average Trading Volume: 1,872,956
Technical Sentiment Signal: Buy
Current Market Cap: HK$287.9M
See more data about 2197 stock on TipRanks’ Stock Analysis page.